|
Market Closed -
Euronext Paris
09:25:00 23/09/2026 pm IST
|
Pre-market 12:00:15 pm | |||
| 7.850 EUR | -5.65% |
|
7.813 | -0.47% |
| Market Cap | 8.09Cr 9.22Cr 7.6Cr 6.95Cr 13Cr 882.87Cr 13Cr 91Cr 35Cr 450.12Cr 35Cr 34Cr 1.46TCr | P/E 2026 * |
-2.29x | P/E 2027 * | -5.26x |
|---|---|---|---|---|---|
| Enterprise Value | 68.94L 78.54L 64.8L 59.25L 1.11Cr 75Cr 1.12Cr 7.78Cr 3.02Cr 38Cr 2.95Cr 2.88Cr 124.37Cr | EV / Sales 2026 * |
3.45x | EV / Sales 2027 * | 0.32x |
| Free-Float |
70.51% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALSEN | Real-time | |
CBOE
| Real-time | ||
|
Tradegate
| RFM | Real-time | |
|
Börse Stuttgart
| RFM | Delayed | |
|
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Börse Stuttgart
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time |
| 1 day | -5.65% | ||
| 1 week | -19.07% | ||
| Current month | -41.64% | ||
| 1 month | -42.91% | ||
| 3 months | -36.69% | ||
| 6 months | -61.71% | ||
| Current year | -53.41% |
| 1 week | 7.4 |  | 9.68 |
| 1 month | 7.4 | | 14.2 |
| Current year | 7.4 | | 40.4 |
| 1 year | 7.4 | | 40.4 |
| 3 years | 7.4 | | 52 |
| 5 years | 7.4 | | 114.5 |
| 10 years | 7.4 | | 387 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frédéric Chéreau
CEO | Chief Executive Officer | 59 | 01/06/2026 |
Laurene Danon
DFI | Director of Finance/CFO | - | 26/06/2024 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 11/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 09/03/2015 | |
Julien Miara
BRD | Director/Board Member | 43 | - |
Khalil Barrage
CHM | Chairman | 61 | 30/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/02/26 | Redmile Biopharma Investments III LP
| Buy | Company | 1,89,28,571 | 6.2956% | |
| 31/01/26 | Sofinnova Partners SAS
| Buy | Company | 1,07,14,285 | 3.5636% | |
| 18/04/24 | Redmile Biopharma Investments III LP
| Buy | Company | 27,81,914 | 1.0091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.65% | -19.07% | -50.16% | -77.57% | 9.22Cr | |
| -0.18% | +4.35% | +4.23% | +31.79% | 4.76TCr | |
| -0.83% | -0.36% | +43.66% | +34.77% | 4.41TCr | |
| -0.84% | +4.86% | +10.92% | +91.52% | 4.15TCr | |
| -1.10% | -2.64% | +331.49% | +535.80% | 4.09TCr | |
| -0.62% | +0.11% | +1.12% | +46.02% | 2.97TCr | |
| -2.07% | +0.12% | +24.39% | +154.30% | 1.72TCr | |
| -3.55% | +1.95% | +21.97% | +38.83% | 1.51TCr | |
| -6.08% | -9.92% | - | - | 1.47TCr | |
| -0.78% | +9.46% | -8.96% | - | 1.38TCr | |
| Average | -2.07% | -1.29% | +42.07% | +106.93% | 2.65TCr | |
| Weighted average by Cap. | -1.10% | +0.95% | +67.18% | +141.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20L 22.79L 18.8L 17.19L 32.12L 22Cr 32.36L 2.26Cr 87.54L 11Cr 85.57L 83.7L 36Cr | 1.82Cr 2.07Cr 1.71Cr 1.56Cr 2.92Cr 198.23Cr 2.94Cr 21Cr 7.95Cr 101.07Cr 7.77Cr 7.6Cr 327.68Cr |
| Net income | -3.5Cr -3.98Cr -3.29Cr -3Cr -5.61Cr -381.44Cr -5.65Cr -39Cr -15Cr -194.47Cr -15Cr -15Cr -630.53Cr | -1.74Cr -1.98Cr -1.63Cr -1.49Cr -2.79Cr -189.36Cr -2.81Cr -20Cr -7.59Cr -97Cr -7.42Cr -7.26Cr -313.01Cr |
| Net Debt | -7.4Cr -8.43Cr -6.96Cr -6.36Cr -12Cr -807.63Cr -12Cr -84Cr -32Cr -411.76Cr -32Cr -31Cr -1.34TCr | -7.5Cr -8.55Cr -7.05Cr -6.45Cr -12Cr -818.55Cr -12Cr -85Cr -33Cr -417.32Cr -32Cr -31Cr -1.35TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | €7.850 | -5.65% | 72,744 |
| 22/26/22 | €8.320 | -3.59% | 12,445 |
| 21/26/21 | €8.630 | -6.06% | 14,178 |
| 18/26/18 | €9.187 | -2.29% | 14,402 |
| 17/26/17 | €9.402 | -3.07% | 15,998 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALSEN Stock
Select your edition
All financial news and data tailored to specific country editions
